EPISODE · May 2, 2014 · 9 MIN
The Lancet Oncology: May 02, 2014
from Listen to The Lancet Oncology · host The Lancet
Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.
Embed this episode
NOW PLAYING
The Lancet Oncology: May 02, 2014
0:00
9:25
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 9 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on May 2, 2014.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!